FDA spurns Lilly, Boehringer diabetes drug, cites factory problem

March 5 Wed Mar 5, 2014 9:53am EST

March 5 (Reuters) - Eli Lilly and Co and partner Boehringer Ingelheim said U.S. regulators have declined to approve their experimental diabetes drug empagliflozin, citing previously observed deficiencies at a manufacturing facility where it would be made.

The drugmakers, in a joint release on Wednesday, said the U.S. Food and Drug Administration determined that deficiencies at the Boehringer Ingelheim factory would have to be resolved before the product could be approved.

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.